IXICO plc (IXI) AI Stock Analysis

• Market Cap: £11.35M
• Dividend Yield: N/A
• Average Volume (3M): 97.07K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.00
• Revenue Growth: 7.27%
• EPS Growth: 39.64%
• Country: UK
• Employees: 81
• Sector: Healthcare
• Sector Strength: 58
• Industry: Biotechnology
• EPS (TTM): -0.01
• Shares Outstanding: 92,668,594
• 10 Day Avg. Volume: 166,494
• 30 Day Avg. Volume: 97,074
• PEG Ratio: 0.37
• Price to Book (P/B): 0.57
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -6.01
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 60 Neutral
• Price Target: 12.00p ▲(6.67%Upside)

IXICO plc's stock score reflects a mix of challenges and opportunities. Financial struggles due to declining revenue and profitability issues weigh on the score, however, positive technical indicators and strategic corporate events suggest potential growth and stability in the medium term. The absence of a profitable valuation metric is offset by promising corporate developments.

IXICO plc Business Overview & Revenue Model

Company Description

IXICO plc provides data analytics services to the biopharmaceutical industry in the United Kingdom, Switzerland, Netherlands, Ireland, rest of Europe, the United States, and internationally. Its services include collection, analysis, management, and reporting on data generated in the course of a clinical study. The company's technologies comprise Assessa, a secure online digital platform that provides clinical decision support for patient selection and post-marketing surveillance; and TrialTracker, a platform that delivers imaging services designed to manage the complex imaging workflow from image upload, quality control, and reading/analysis to reporting and data transfer. Its focused therapeutic areas include Alzheimer's, Parkinson's, Huntington's, Multiple Sclerosis and other demyelinating diseases, Progressive Supranuclear Palsy, and other rare neurological diseases. The company also engages in the data collection, optimization, and analytics of rare neurological disorders; offers drug development analytics, imaging operation services, and post marketing surveillance services, as well as consultancy services; and provides end-to-end services, such as trail design and consultation, project management, imaging site set-up and management, data management, reading and analysis, and regulatory pathway. IXICO plc was incorporated in 1995 and is based in London, the United Kingdom.

How the Company Makes Money

IXICO plc generates revenue by offering its specialized data analytics and digital biomarker solutions to pharmaceutical and biotechnology companies engaged in clinical trials. Key revenue streams include service contracts for imaging data analysis, digital biomarker development, and consultation services. The company leverages its proprietary technology platform to provide these services, thereby supporting drug development processes. Additionally, IXICO may enter into strategic partnerships with clinical research organizations and pharmaceutical firms, which can contribute to its earnings through collaborative projects and long-term service agreements.

IXICO plc Financial Statement Overview

Summary

IXICO plc is facing financial challenges with declining revenue and negative profit margins. Despite a strong equity position, cash flow issues and negative return on equity highlight significant profitability concerns.

Income Statement

The company has experienced a significant decline in revenue over the past year, with a negative revenue growth rate of 13.48% from 2023 to 2024. Both EBIT and EBITDA margins are negative, indicating operational challenges and inefficiencies. The net profit margin is also negative, reflecting ongoing struggles to achieve profitability.

Balance Sheet

The company maintains a strong equity position with an equity ratio of 84.57%, indicating financial stability. However, the debt-to-equity ratio is low at 0.03, suggesting limited leverage which could restrict growth opportunities. Return on Equity is negative, further highlighting profitability issues.

Cash Flow

The company has faced a substantial decline in free cash flow, dropping from -1.66 million in 2023 to -2.20 million in 2024. The operating cash flow to net income ratio is negative, indicating cash flow difficulties. Additionally, the free cash flow to net income ratio suggests challenges in converting earnings to cash.

Breakdown
Sep 2024	Sep 2023	Sep 2022	Sep 2021	Sep 2020
Income Statement		Total Revenue
5.77M	6.67M	8.64M	9.19M	9.53M
	Gross Profit
2.71M	3.27M	4.77M	5.53M	5.91M
	EBIT
-2.15M	-1.44M	111.00K	698.00K	236.00K
	EBITDA
-1.95M	-707.00K	750.00K	1.31M	674.00K
	Net Income Common Stockholders
-2.00M	-1.18M	1.03M	1.51M	952.00K
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
1.79M	4.03M	5.77M	6.68M	7.95M
	Total Assets
11.19M	12.99M	14.65M	14.26M	12.10M
	Total Debt
314.00K	387.00K	516.00K	597.00K	213.00K
	Net Debt
-1.47M	-3.64M	-5.25M	-6.09M	-7.73M
	Total Liabilities
1.72M	1.56M	2.16M	2.78M	2.98M
	Stockholders Equity
9.46M	11.43M	12.49M	11.48M	9.12M
Cash Flow		Free Cash Flow
-2.20M	-1.66M	-815.00K	-1.54M	795.00K
	Operating Cash Flow
-1.73M	302.00K	1.43M	614.00K	1.94M
	Investing Cash Flow
-377.00K	-1.86M	-2.25M	-2.15M	-1.14M
	Financing Cash Flow
-134.00K	-156.00K	-114.00K	270.00K	-112.00K

IXICO plc Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 11.25
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:IXI, the sentiment is Neutral. The current price of 11.25 is below the 20-day moving average (MA) of 11.47, above the 50-day MA of 9.75, and above the 200-day MA of 10.25, indicating a neutral trend. The MACD of 0.63 indicates Positive momentum. The RSI at 51.56 is Neutral, neither overbought nor oversold. The STOCH value of 37.04 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for GB:IXI.

IXICO plc Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
IXI	60 Neutral	£11.35M	―	-13.85%	―	7.27%	39.64%
APTA	54 Neutral	£6.57M	―	-99.43%	―	17.39%	96.02%
Sector *	54 Neutral	$5.41B	3.27	-45.10%	3.29%	16.81%	0.02%
OBD	50 Neutral	£7.34M	―	-222.16%	―	24.71%	38.28%
ONC	32 Underperform	$1.27M	1.35		―	137.76%	-193.86%
CIZ		£6.94M	―	-272.62%	―	―	―
FAB	44 Neutral	£7.56M	―	-129.49%	―	14.12%	78.16%

IXICO plc Corporate Events

IXICO plc Issues Share Options and Announces Director Share Dealings

IXICO plc announced the issuance of 850,000 share options to key executives, including the Chief Technology Officer and Chief Business Officer, as part of a retention strategy linked to annual share price growth over three years. Additionally, the company’s CFO/COO, Grant Nash, conducted a share transaction involving the sale and repurchase of shares into his ISA account, maintaining his beneficial interest in the company.

IXICO Facilitates FDA Clearance of Alzheimer’s Blood-Based Diagnostic

IXICO has played a pivotal role in the validation of a new Alzheimer’s Disease diagnostic biomarker for Fujirebio Diagnostics, Inc., leading to the first FDA clearance of a blood-based in vitro diagnostic test for Alzheimer’s in the U.S. This milestone enhances IXICO’s capabilities in neuroimaging biomarker analyses and marks a significant advancement in early-stage Alzheimer’s diagnosis, potentially improving patient outcomes through earlier intervention.

IXICO plc Announces Shareholder Name Change Notification

IXICO plc has announced a notification of major holdings due to a name change of a shareholder from Amati AIM VCT plc to Maven Renovar VCT PLC, following a change in the investment manager to Maven Capital Partners UK LLP. This notification does not indicate any change in the position held by the company, serving purely as an informational update about the name change.

IXICO Reports Revenue Growth and Strategic Expansion in H1 2025

IXICO plc reported a 26% increase in revenue to £3.2 million for the first half of 2025, driven by diversified projects and strategic expansion in neurological disease areas. The company strengthened its operations with key hires, expanded its US footprint, and announced significant commercial partnerships, positioning itself for growth in neurodegenerative disease research.

IXICO Announces Change in Investment Manager for Major Shareholder

IXICO plc announced a change in the investment manager for Amati AIM VCT plc to Maven Capital Partners UK LLP, resulting in a name change to Maven Renovar VCT plc. Despite this change, there has been no alteration in the position held in IXICO, indicating stability in the company’s shareholder structure. This announcement reflects IXICO’s ongoing commitment to maintaining its operational stability and shareholder confidence, crucial for its strategic positioning in the neuroscience research industry.

IXICO plc to Announce Interim Results and Host Investor Presentation

IXICO plc announced it will release its unaudited interim results for the six months ending 31 March 2025 on 20 May 2025. The company will host a live presentation for shareholders to discuss these results and its ongoing strategy. This event underscores IXICO’s commitment to transparency and engagement with its stakeholders, reinforcing its position as a leader in the neuroscience imaging industry.

IXICO plc Reports Strong First Half 2025 Performance and Strategic Expansion

IXICO plc reported a 26% increase in revenues for the first half of 2025, reaching £3.2 million, and a strong cash balance of £5.0 million. The company has expanded its operations in the US and is enhancing its imaging biomarker analysis for Alzheimer’s and Parkinson’s diseases. This strategic focus is expected to lead to further contract wins in these areas, with increased investment anticipated to boost revenues in 2026 and beyond.